View our Market Insights webinar that features an enlightening exploration of the intersection between mental health and rare diseases.
Market Insights Program
Uncovering Practical Managed Care Insights for Population Management
Latest Research
People with rare diseases often have mental health challenges related to their health care. These vary by disease, but there are common issues that make it difficult for individuals and their families, including delays in getting diagnosed, not knowing what will happen in the future, having limited treatments, and facing financial difficulties.
The AMCP Poster Abstract Program provides a forum for authors to share their research with the managed care pharmacy community.
Market Insights Webinars
View More WebinarsPublished Disease Research
Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm). It is characterized by a progressive accumulation of functionally incompetent B lymphocytes, which are usually monoclonal in origin.
Hear from a panel of experts discuss the role of BTKi's in the management of chronic lymphocytic leukemia (CLL)
Diabetes technology is the hardware, devices, and software that people with diabetes use to help manage their condition. Diabetes technology has expanded to include complex devices that both monitor blood sugar and deliver insulin. The American Diabetes Association now recommends use of continuous glucose monitoring (CGM) in individuals with both type 1 and type 2 diabetes. Rapid change in the diabetes technology landscape may lead to access barriers that can impact health plan programs, necessitating appropriate coverage policies.
AMCP brought together experts to learn about food allergies caused by the body reacting strongly to certain foods. Food allergies can be difficult to handle and costly for both people and the health care system. New medicines could help prevent allergic reactions, including anaphylaxis, caused by accidental exposure to foods. It is important for health care leaders to make sure people with food allergies see the right doctors, get the right medicine at the right time, and help prevent allergic reactions and related health care costs.
JMCP Findings - Bridging the Gaps in Precision Oncology: Opportunities in Non-Small Cell Lung Cancer
Lung cancer is the most common cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. The National Institutes of Health estimated that cancer care cost the US $208.9 billion in 2020, $23.8 billion of which was due to lung cancer.
View our Market Insights webinar to explore the latest practice recommendations in the management and treatment of food allergies.
AMCP brought together experts to learn about food allergies caused by the body reacting strongly to certain foods. Food allergies can be difficult to handle and costly for both people and the health care system. New medicines could help prevent allergic reactions, including anaphylaxis, caused by accidental exposure to foods. It is important for health care leaders to make sure people with food allergies see the right doctors, get the right medicine at the right time, and help prevent allergic reactions and related health care costs.
Hemophilia, sickle cell disease (SCD), and beta thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies.
Hear from a panel of experts discussing bridging the gaps in precision oncology: opportunities in non-small cell lung cancer
Chronic lymphocytic leukemia (CLL) is a chronic
lymphoproliferative disorder (lymphoid neoplasm).
It is characterized by a progressive accumulation of
functionally incompetent B lymphocytes, which are
usually monoclonal in origin.
Hear from a panel of experts discussing exploring opportunities to improve quality of life for those with Amyotrophic Lateral Sclerosis (ALS).
The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.
Expert Faculty
Ryan Haumschild, PharmD, MS, MBA
Moderator
Director of Pharmacy Services, Emory Healthcare and Winsor Cancer Institute
Tim Mok, PharmD, BCPS, BСОР
Hematology Oncology Pharmacy Research Analyst, Kaiser Permanente
Laura Bobolts, PharmD, BСОР
Senior Vice President, Clinical Strategy and Growth, OncoHealth
Jorge Garcia, PharmD, MS, MHA, MBA, FACHE
Assistant Vice President, System Oncology Pharmacy, Baptist Health
Susan Wescott, R. Ph, MBA
Senior Director of Pharmacy, Managed Care Mayo Clinic
Wendy Bailey, RPh, BSPharm, MSPharm, MBA
Principal, Bailey Healthcare Consulting
Upcoming Disease Research
Idiopathic Hypersomnia
Discover the impact of excessive daytime sleepiness (EDS) and idiopathic hypersomnia (IH) on quality of life, prevalence, and disease burden, along with advancements in screening, diagnosis, and treatment strategies, including payer insights and considerations for emerging therapies.
- Listen to the Roundtable Webinar - Coming Soon
- Read the findings in JMCP - Coming Soon
Retinal Disease Management
Explore opportunities for interdisciplinary Retinal Disease Management from a panel of Chief Medical and Pharmacy Officers.
- Read the findings in JMCP - Coming Soon
View the Infographic - Coming Soon
Multiple Sclerosis
Gain insights into the development and types of multiple sclerosis (MS), advancements in treatment options, and the role of guidelines and health care coverage in shaping effective MS management strategies through expert collaboration.
- Listen to the Roundtable Webinar - Coming Soon
Read the findings in JMCP - Coming Soon
Breast Cancer
Precision Oncology
Explore strategies to optimize biomarker-driven oncology decision-making by addressing barriers to testing and treatment selection, leveraging precision medicine to improve patient outcomes, and engaging diverse stakeholder perspectives to develop actionable best practices for oncology care.
- Read the findings in JMCP - Coming Soon
View the Nexus 2024 Poster Abstract
